Effect of lipopolysaccharide on TAK1 -mediated hepatocyte PANoptosis through Toll -like receptor 4 during acute liver failure

Wenyuan Li,Wenbin Zhang,Danmei Zhang,Chunxia Shi,Yao Wang
DOI: https://doi.org/10.1016/j.intimp.2024.111612
IF: 5.714
2024-02-10
International Immunopharmacology
Abstract:Background Intestinal endotoxemia (IETM) is an important pathogenic mechanism of acute liver failure (ALF), and TAK1 -mediated PANoptosis is a novel cell death mode. This study investigated whether IETM can induce hepatocyte PANoptosis during ALF. Method PANoptosis cell and mouse models were generated, and lentiviruses (LVs), adeno-associated viral vectors (AVVs), and small interfering RNAs (siRNAs) were subsequently used to overexpress or knock down TLR and TAK1. Then, the levels of hepatocyte injury, TLR4 , TAK1 and PANoptosis were detected via an enzyme-labeling instrument, tissue staining, RT–PCR, western blotting, immunofluorescence, and flow cytometry. Results The BioGRID database search revealed that TAK1 might interact with TLR4 . According to the in vivo experiments, compared with those in ALF mice, liver tissue damage, hepatocyte mortality and PANoptosis in mice in the AAV- TAK1 group were significantly lower, and liver function was significantly improved. According to the in vitro experiments, after promoting the expression of TLR4 in the model group, the degree of cell damage, TLR4 expression and PANoptosis further increased, while the level of TAK1 further decreased. The opposite result was obtained when TLR4 expression was inhibited. The increase in TAK1 expression in the model group reduced the degree of cell damage and PANoptosis, but the level of TLR4 was not significantly changed. In the model group of cells that exhibited TAK1 expression, further promotion of TLR4 expression inhibited the protective effect of TAK1 on cells. In the model group of cells after TAK1 expression was promoted, if the expression of TLR4 was further promoted, the protective effect of TAK1 on cells was inhibited. Conclusion IETM inhibited the expression of TAK1 by binding to TLR4 molecules and promoting hepatocyte PANoptosis during ALF. Promoting TAK1 expression effectively relieved lipopolysaccharide-induced hepatocyte PANoptosis.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?